- Home
- URGN vs TREE Comparison
URGN vs TREE Comparison
Compare URGN & TREE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- TREE
- Stock Information
- Founded
- URGN 2004
- TREE 1996
- Country
- URGN United States
- TREE United States
- Employees
- URGN N/A
- TREE N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- TREE Finance: Consumer Services
- Sector
- URGN Health Care
- TREE Finance
- Exchange
- URGN Nasdaq
- TREE Nasdaq
- Market Cap
- URGN 463.2M
- TREE 549.4M
- IPO Year
- URGN 2017
- TREE N/A
- Fundamental
- Price
- URGN $10.38
- TREE $38.70
- Analyst Decision
- URGN Strong Buy
- TREE Buy
- Analyst Count
- URGN 7
- TREE 8
- Target Price
- URGN $36.75
- TREE $64.13
- AVG Volume (30 Days)
- URGN 635.6K
- TREE 513.8K
- Earning Date
- URGN 05-12-2025
- TREE 05-01-2025
- Dividend Yield
- URGN N/A
- TREE N/A
- EPS Growth
- URGN N/A
- TREE N/A
- EPS
- URGN N/A
- TREE N/A
- Revenue
- URGN $90,398,000.00
- TREE $972,179,000.00
- Revenue This Year
- URGN $36.82
- TREE $14.31
- Revenue Next Year
- URGN $119.10
- TREE $7.39
- P/E Ratio
- URGN N/A
- TREE N/A
- Revenue Growth
- URGN 9.29
- TREE 51.96
- 52 Week Low
- URGN $8.94
- TREE $34.55
- 52 Week High
- URGN $20.70
- TREE $62.49
- Technical
- Relative Strength Index (RSI)
- URGN 48.46
- TREE 39.00
- Support Level
- URGN $9.63
- TREE $36.71
- Resistance Level
- URGN $11.75
- TREE $54.81
- Average True Range (ATR)
- URGN 0.82
- TREE 2.86
- MACD
- URGN -0.02
- TREE -1.24
- Stochastic Oscillator
- URGN 32.90
- TREE 10.99
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About TREE LendingTree Inc.
LendingTree Inc. is a U.S.-based company that mainly operates an online loan marketplace. The company offers online tools and resources to help consumers find loans or other credit-based products, including mortgage loans, reverse mortgages, home equity loans, personal loans, auto loans, credit cards, student loans, small business loans, and various related products. It provides consumers with direct access to a wide array of lenders. The company has three reportable segments: Home, Consumer, and Insurance. It generates match fees by connecting consumers with lenders and closing fees from lenders when a transaction is finalized. The company conducts business solely in the United States.